Generalized anxiety disorder. Generalized anxiety disorder
Conditions
Interventions
Intervention 1: Intervention group: Participants in the treatment group will receive 200 mg of silymarin supplement (made by Goldaru Pharmaceutical Company) twice daily for 12 weeks. Intervention 2: C
Sponsors
Bagheiat-allah University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Participants must be between 18 and 65 years of age. Participants must have a diagnosis of generalized anxiety disorder (GAD) and depression. Participants must not be currently taking any medications for their condition. Participants must be able to provide Informed Consent Form. Participants must be willing to comply with the study protocol for the duration of the study. Participants must not have any known allergies or adverse reactions to silymarin. Participants must not have any significant medical conditions that may interfere with the results of the study. Participants must not be pregnant or breastfeeding. Participants must not have participated in any other clinical trial in the past three months. Participants must be able to attend all study visits and complete all study assessments.
Exclusion criteria
Exclusion criteria: Participants under 18 years of age or over 65 years of age. Participants without a diagnosis of generalized anxiety disorder (GAD) and depression. Participants currently taking medication for their condition. Participants unable to provide Informed Consent Form. Participants unwilling to comply with the study protocol for the duration of the study. Participants with known allergies or adverse reactions to silymarin. Participants with significant medical conditions that may interfere with the study results. Participants who are pregnant or breastfeeding. Participants who have participated in any other clinical trial in the past three months. Participants unable to attend all study visits and complete all study assessments.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Generalized anxiety. Timepoint: Before and 12 months after the intervention. Method of measurement: Beck Anxiety Inventory. | — |
Secondary
| Measure | Time frame |
|---|---|
| Plasma levels of the cortisol hormone. Timepoint: Before and 12 months after the intervention. Method of measurement: ELISA method and cortisol detection kit.;Plasma levels of vitamin D. Timepoint: Before and 12 months after the intervention. Method of measurement: HPLC.;Plasma levels of thyroid hormones. Timepoint: Before and 12 months after the intervention. Method of measurement: immunochemiluminometric assay (ICMA). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactKarim Parastouei
Bagheiat-allah University of Medical Sciences
Outcome results
None listed